3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Lung Neoplasms
10
Small Cell Lung Carcinoma
9
Mesothelioma, Malignant
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
4
Mesothelioma
3
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Part A and B: Advanced Solid Malignancies
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Lung Cancer Metastatic
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
EGFR Mutant Advanced Non Small Cell Lung Cancer
1
Disease Progression
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Renal Cell
1
Interventions
Carboplatin
24
Pemetrexed
18
Cisplatin
17
Paclitaxel
14
pembrolizumab
13
Gemcitabine
8
osimertinib
7
durvalumab
6
Docetaxel
6
Nivolumab
5
Erlotinib Hydrochloride
5
130-nm albumin-bound paclitaxel
5
capmatinib
3
brigatinib
3
anlotinib
3
Gefitinib
3
Drug Therapy
3
vosaroxin
2
volociximab
2
sintilimab
2
pralsetinib
2
ensartinib
2
atezolizumab
2
aflibercept
2
Surgical Procedures, Operative
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Oncolytic Virotherapy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
tremelimumab
×
Thoracic
×
Clear all
NCT03703297
2025-11-21
ADRIATIC
AstraZeneca
Phase 3
Active not recruiting
730 enrolled
19 charts
1 FDA